Caredx announces new ivd products and ivdr certification for alloseq® tx and qtype® at the 2025 american society of histocompatibility & immunogenetics annual meeting

South san francisco, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new innovations and products that will be featured at the american society for histocompatibility and immunogenetics (ashi) 2025 annual meeting, held october 6th to 10th in orlando.
CDNA Ratings Summary
CDNA Quant Ranking